Savant Capital LLC Sells 20,965 Shares of Gilead Sciences, Inc. $GILD

Savant Capital LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 43.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,084 shares of the biopharmaceutical company’s stock after selling 20,965 shares during the quarter. Savant Capital LLC’s holdings in Gilead Sciences were worth $3,324,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after acquiring an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. lifted its holdings in shares of Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after acquiring an additional 7,168 shares during the last quarter. NewEdge Wealth LLC increased its stake in shares of Gilead Sciences by 2.9% in the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after buying an additional 17,284 shares during the period. Nordea Investment Management AB increased its stake in shares of Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after buying an additional 726,101 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Gilead Sciences by 4.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 161,155 shares of the biopharmaceutical company’s stock valued at $17,888,000 after buying an additional 6,680 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent research reports. Daiwa Securities Group lowered their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price objective for the company. Scotiabank upped their price objective on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Finally, Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $156.93.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 53,000 shares of company stock valued at $7,075,670. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $134.43 on Friday. The company has a market capitalization of $166.90 billion, a PE ratio of 18.31 and a beta of 0.31. The company has a 50 day simple moving average of $135.30 and a two-hundred day simple moving average of $134.09. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a fifty-two week low of $104.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.